Compare NBY & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBY | HELP |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.2M | 366.7M |
| IPO Year | 2007 | N/A |
| Metric | NBY | HELP |
|---|---|---|
| Price | $1.47 | $7.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 591.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.42 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $370,000.00 | N/A |
| Revenue This Year | $23.91 | N/A |
| Revenue Next Year | $32.05 | N/A |
| P/E Ratio | $1.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $5.76 |
| 52 Week High | $19.95 | $8.23 |
| Indicator | NBY | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 58.71 |
| Support Level | $0.94 | $7.33 |
| Resistance Level | $2.66 | $8.23 |
| Average True Range (ATR) | 0.24 | 0.62 |
| MACD | 0.30 | 0.16 |
| Stochastic Oscillator | 43.78 | 89.74 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.